Company intelligence / Profile preview

Arete Therapeutics Inc.

Hayward, California, United Statesaretetherapeutics.net ↗

Ownership: Private
Development stage: Preclinical

Overview

AR9281, the company's lead compound, completed Phase 1 clinical trials successfully, demonstrating safety and tolerability in healthy volunteers. A Phase 2a multicenter, double-blind, placebo-controlled study was initiated in 2009 for pre-diabetic patients with impaired glucose tolerance, mild obesity, and mild to moderate hypertension. Results were expected in Q1 2010.

Therapeutic areas: ImmunologyEndocrinologyCardiovascularMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

AR-9281

Beyond the preview

Go deeper on Arete Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arete Therapeutics Inc..

Explore the full profile